Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Recipient : Johns Hopkins University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Allosteric Licenses Sarcopenia Therapy Tech from Johns Hopkins
Details : The licensed technology covers the use of inhibitors of an enzyme termed GCPII (glutamate carboxypeptidase II) for the treatment of sarcopenia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 06, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Recipient : Johns Hopkins University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
